Jón Ingi Benediktsson has joined Akthelia as General Manager. Jón Ingi has extensive experience in biotech investments. He was the CEO of Líftæknisjóðurinn (MP Bio) from November 2000 – April 2005, then he served as Director for the Akureyri University Research and Innovation Center. From January 2008 he was member of SEED Capital, the largest early stage venture fund in Denmark, life science investment team as Investment Manager and later on as Investment Director, responsible for their overall early stage life science investments. Akthelia is looking forward to having him on board.

Birgitta Agerberth, Director of Medical Microbial Pathogenesis of Akthelia Pharmaceuticals was one of two vice-chairs of the conference and also acted as a Discussion Leader during the session on „Understanding biology through the AMPs“. Guðmundur Hrafn Guðmundsson, Chairman of Akthelia‘s board of directors was a discussion leader during the session on „Regulation of AMP expression“ and presented his work in a poster. The participation of Drs Agerberth and Guðmundsson in the conference further establishes their leading role in the field of antibacterial peptides.